Augmented Anticancer Efficacy of Doxorubicin-Loaded Polymeric Nanoparticles after Oral Administration in a Breast Cancer Induced Animal Model
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
The present investigation reports an extensive evaluation of in vitro and in vivo anticancer efficacy of orally administered doxorubicin-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles (Dox-NPs) in a breast cancer induced animal model. Spherically shaped Dox-NPs were prepared with an entrapment efficiency and particle size of 55.40 ± 2.30% and 160.20 ± 0.99 nm, respectively, and freeze-dried with 5% trehalose using stepwise freeze-drying. Cytotoxicity, as investigated on C127I cell line, revealed insignificant differences between the IC(50) of free Dox and Dox-NPs treated cells in the first 24 h, while higher cytotoxicity was demonstrated by Dox-NPs, following 72 h of incubation. Confocal laser scanning microscopy (CLSM) imaging corroborated that nanoparticles were efficiently localized into the nuclear region of C127I cells. The cellular uptake profile of Dox-NPs revealed both time and concentration dependent increases in the Caco-2 cell uptake as compared to the free Dox solution. Further, Dox-NPs significantly suppressed the growth of breast tumor in female Sprague-Dawley (SD) rats upon oral administration. Finally, orally administered Dox-NPs showed a marked reduction in cardiotoxicity when compared with intravenously injected free Dox as also evident by the increased level of malondialdehyde (MDA), lactate dehydrogenase (LDH), and creatine phosphokinase (CK-MB) and reduced levels of glutathione (GSH) and superoxide dismutase (SOD). The reduced cardiotoxicity of orally administered Dox-NPs was also confirmed by the major histopathological changes in the heart tissue after the treatments of intravenously injected free Dox and orally delivered Dox-NPs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“when the efficacy of WGA-coated allergen-loaded microspheres was evaluated in birch pollen-sensitized mice, oral treatment did not induce an allergen-specific isotype switch towards IgG2a or the production of the Th1 cytokine IFN-γ in comparison to gavages of plain microspheres [74].”
From Use of lectin-functionalized particles for oral immunotherapy (2012) · cites this paper as [74]
In the citing paper
“in a 7,12-dimethylbenz[a]anthracene-induced breast cancer rat model, oral administration of doxorubicin loaded PLGA NPs revealed a higher antitumor efficacy as a result of enhanced bioavailability, tumor permeation and retention effect [74].”
From Use of lectin-functionalized particles for oral immunotherapy (2012) · cites this paper as [74]
In the citing paper
“incorporation of doxorubicin into PLGA nanospheres significantly reduced the doxorubicin-induced cardiotoxicity [74].”
From Use of lectin-functionalized particles for oral immunotherapy (2012) · cites this paper as [74]
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
Doxorubicin-Induced Cardiomyopathy
Singal, P. K., & Iliskovic, N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809243391307 · Cited by 1,845
Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies
Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,634
Freeze-drying of nanoparticles: Formulation, process and storage considerations
ABDELWAHED, W., DEGOBERT, G., STAINMESSE, S., & FESSI, H. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.017 · Cited by 1,611
Expression of a multidrug-resistance gene in human tumors and tissues.
Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M., & Pastan, I. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.1.265 · Cited by 1,544
Yin Win, K., & Feng, S.-S. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2004.07.050 · Cited by 1,452
Govender, T. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(98)00116-3 · Cited by 1,008
Artursson, P. (1990) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600790604 · Cited by 844
Synthesis and characterization of PLGA nanoparticles
Astete, C. E., & Sabliov, C. M. (2006) · Journal of Biomaterials Science, Polymer Edition · doi:10.1163/156856206775997322 · Cited by 776
Chitosan nanoparticles as delivery systems for doxorubicin
Janes, K. A., Fresneau, M. P., Marazuela, A., Fabra, A., & Alonso, M. J. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00294-2 · Cited by 721
Research works printed but not linked: 3
- Bardelmeijer H. A., 2000, Clin. Cancer Res., 6, 4416
- Rehm S., 1990, Am. J. Pathol., 136, 575
- Ballinger J. R., 1996, J. Nucl. Med., 37, 1578
Cited by
Oral delivery of anticancer drugs: Challenges and opportunities
Thanki, K., Gangwal, R. P., Sangamwar, A. T., & Jain, S. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.020 · Cited by 499
Self-citationJain, A. K., Thanki, K., & Jain, S. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400311j · Cited by 235
Self-citationHSA Coated Iron Oxide Nanoparticles as Drug Delivery Vehicles for Cancer Therapy
Quan, Q., Xie, J., Gao, H., Yang, M., Zhang, F., Liu, G., Lin, X., Wang, A., Eden, H. S., Lee, S., et al. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200006f · Cited by 223
Jain, S., Rathi, V. V., Jain, A. K., Das, M., & Godugu, C. (2012) · Nanomedicine · doi:10.2217/nnm.12.31 · Cited by 174
Self-citationAgrawal, A. K., Harde, H., Thanki, K., & Jain, S. (2014) · Biomacromolecules · doi:10.1021/bm401580k · Cited by 170
Self-citationOral Delivery of Doxorubicin Using Novel Polyelectrolyte-Stabilized Liposomes (Layersomes)
Jain, S., Patil, S. R., Swarnakar, N. K., & Agrawal, A. K. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300202c · Cited by 158
Self-citationDatir, S. R., Das, M., Singh, R. P., & Jain, S. (2012) · Bioconjugate Chemistry · doi:10.1021/bc300248t · Cited by 145
Self-citationRecent Advances in Doxorubicin Formulation to Enhance Pharmacokinetics and Tumor Targeting
Lee, J., Choi, M., & Song, I. (2023) · Pharmaceuticals · doi:10.3390/ph16060802 · Cited by 160
Liang, Y., Deng, X., Zhang, L., Peng, X., Gao, W., Cao, J., Gu, Z., & He, B. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.08.032 · Cited by 141
Das, M., Datir, S. R., Singh, R. P., & Jain, S. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300701e · Cited by 136
Self-citationGelatin Coated Hybrid Lipid Nanoparticles for Oral Delivery of Amphotericin B
Jain, S., Valvi, P. U., Swarnakar, N. K., & Thanki, K. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300320d · Cited by 134
Self-citationSingh, A., Neupane, Y. R., Mangla, B., & Kohli, K. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.06.003 · Cited by 129
Jain, S., Jain, A., Pohekar, M., & Thanki, K. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.05.041 · Cited by 122
Self-citationSingh, R. P., & Ramarao, P. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft179 · Cited by 114
Self-citationJ, R. J. P., Oluwafemi, O. S., Thomas, S., & Oyedeji, A. O. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103390 · Cited by 123
Tariq, M., Alam, A., Singh, A. T., Iqbal, Z., Panda, A. K., & Talegaonkar, S. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.02.043 · Cited by 100
Duo, Y., Yang, L., Chen, C., Liu, B., Wang, X., Zeng, X., & Chen, H. (2017) · RSC Advances · doi:10.1039/c7ra05135b · Cited by 96
Jain, S., Gollapalli, S., Agrawal, A. K., Kushwah, V., & Thanki, K. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00281 · Cited by 91
Self-citationNanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability
Kaithwas, V., Dora, C. P., Kushwah, V., & Jain, S. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.03.006 · Cited by 86
Self-citationGolla, K., Bhaskar, C., Ahmed, F., & Kondapi, A. K. (2013) · Journal of Cancer · doi:10.7150/jca.7093 · Cited by 85
Ahmad, N., Ahmad, R., Alam, M. A., & Ahmad, F. J. (2018) · Chemistry Central Journal · doi:10.1186/s13065-018-0434-1 · Cited by 78
“PLGA-NPs was also investigated whereby an improvement in gemcitabine pharmacokinetic profile [28] as well as an enhanced pharmacodynamics profile was observed for doxorubicin and paclitaxel [29, 30].”
BackgroundTian, M.-P., Song, R.-X., Wang, T., Sun, M., Liu, Y., & Chen, X. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.08.146 · Cited by 82
Pathomthongtaweechai, N., & Muanprasat, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060887 · Cited by 86
Swarnakar, N. K., Thanki, K., & Jain, S. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1244-8 · Cited by 79
Self-citationInsights on Development Aspects of Polymeric Nanocarriers: The Translation from Bench to Clinic
Tewari, A. K., Upadhyay, S. C., Kumar, M., Pathak, K., Kaushik, D. K., Verma, R., Bhatt, S., Massoud, E. E. S., Rahman, M. H., & Cavalu, S. D. (2022) · Polymers · doi:10.3390/polym14173545 · Cited by 77
Godugu, C., Doddapaneni, R., & Singh, M. S. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.01.038 · Cited by 70
Self-citationInvestigation of antitumor activities of trastuzumab delivered by PLGA nanoparticles
Colzani, B., Pandolfi, L., Hoti, A., Iovene, P. A., Natalello, A., Avvakumova, S., Colombo, M., & Prosperi, D. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s152742 · Cited by 67
“23,24 Major issues related to protein structural and functional preservation after incorporation and release from PLGA NPs were envisaged.”
Polymer-based drug delivery systems for anticancer drugs: A systematic review
Salari, N., Faraji, F., Torghabeh, F. M., Faraji, F., Mansouri, K., Abam, F., Shohaimi, S., Akbari, H., & Mohammadi, M. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100605 · Cited by 83
Bioabsorbable polymers in cancer therapy: latest developments
Fonseca, A. C., Serra, A. C., & Coelho, J. F. J. (2015) · The EPMA Journal · doi:10.1186/s13167-015-0045-z · Cited by 67
How can nanotechnology help the fight against breast cancer?
Avitabile, E., Bedognetti, D., Ciofani, G., Bianco, A., & Delogu, L. G. (2018) · Nanoscale · doi:10.1039/c8nr02796j · Cited by 61
Jain, A., Thanki, K., & Jain, S. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.12.010 · Cited by 60
Self-citationSingh, R. P., Das, M., Thakare, V., & Jain, S. (2012) · Chemical Research in Toxicology · doi:10.1021/tx300228d · Cited by 56
Self-citationGupta, B., Poudel, B. K., Ruttala, H. B., Regmi, S., Pathak, S., Gautam, M., Jin, S. G., Jeong, J., Choi, H., Ku, S., et al. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.09.006 · Cited by 56
Sheeba, C. J., Marslin, G., Revina, A. M., Khandelwal, V. K. M., Balakumar, K., Prakash, J., & Franklin, G. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s75962 · Cited by 55
Mondal, L., Mukherjee, B., Das, K., Bhattacharya, S., Dutta, D., Chakraborty, S., Pal, M. M., Gaonkar, R. H., & Debnath, M. C. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s220740 · Cited by 54
Chang, L., Liu, J., Zhang, J., Deng, L., & Dong, A. (2012) · Polymer Chemistry · doi:10.1039/c2py20686b · Cited by 51
Deng, L., Dong, H., Dong, A., & Zhang, J. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.10.010 · Cited by 50
Enhanced Transfection Efficiency and Reduced Cytotoxicity of Novel Lipid–Polymer Hybrid Nanoplexes
Jain, S., Kumar, S., Agrawal, A. K., Thanki, K., & Banerjee, U. C. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400036w · Cited by 48
Self-citationEnhanced Intestinal Permeation of Doxorubicin Using Chitosan Nanoparticles
Zare, M., Mohammadi‐Samani, S., & Sobhani, Z. (2018) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2018.048 · Cited by 47
“Dox is an anticancer drug with excellent properties, which is being used to treat several malignancies, such as lymphoma, osteosarcoma and other sarcomas, carcinomas, and melanoma.(14-17) Dox is an anthracycline glycoside antibiotic that inhibits the DNA synthesis and cell proliferation.”
BackgroundDongsar, T. S., Dongsar, T. T., Molugulu, N., Annadurai, S., Wahab, S., Gupta, N., & Kesharwani, P. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116455 · Cited by 54
Swarnakar, N. K., Thanki, K., & Jain, S. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2014.03.003 · Cited by 47
Self-citationPolymeric Nanoparticles for Breast Cancer Therapy: A Comprehensive Review
(2020) · Biointerface Research in Applied Chemistry · doi:10.33263/briac114.1115111171 · Cited by 44
“Doxorubicin hydrochloride PLGA 50:50 Double emulsion diffusion evaporation Reduced cardio-toxicity [53]”
MethodHu, M., Shen, Y., Zhang, L., & Qiu, L. (2016) · Biomacromolecules · doi:10.1021/acs.biomac.5b01676 · Cited by 43
Nanobubbles: A Novel Targeted Drug Delivery System
Pasupathy, R., Pandian, P., & Selvamuthukumar, S. (2022) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902022e19604 · Cited by 42
“The doxorubicin loaded into PLGA nanoparticles is a feasible approach to decrease chemotherapy cytotoxicity to healthy tissues, which help to control undesirable adverse effects viz. impaired cardiac function (Lin, Ng, Wang, 2005; Jain et al., 2011).”
BackgroundDas, M., Singh, R. P., Datir, S. R., & Jain, S. (2013) · Bioconjugate Chemistry · doi:10.1021/bc300598z · Cited by 41
Self-citationUse of lectin-functionalized particles for oral immunotherapy
Diesner, S. C., Wang, X.-Y., Jensen-Jarolim, E., Untersmayr, E., & Gabor, F. (2012) · Therapeutic Delivery · doi:10.4155/tde.11.146 · Cited by 40
Pennetta, C., Floresta, G., Graziano, A. C. E., Cardile, V., Rubino, L. R., Galimberti, M. S., Rescifina, A., & Barbera, V. (2020) · Nanomaterials · doi:10.3390/nano10061073 · Cited by 39
“After the time of incubation, the cells were carefully washed to remove the non-internalized nanotubes, and cytotoxicity was determined by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay according to a previously published protocol [42].”
MethodDas, M., Jain, R., Agrawal, A. K., Thanki, K., & Jain, S. (2014) · Bioconjugate Chemistry · doi:10.1021/bc400477q · Cited by 39
Self-citationAhmad, N., Alam, A., Ahmad, R., Umar, S., & Ahmad, F. J. (2018) · Journal of Microencapsulation · doi:10.1080/02652048.2018.1485755 · Cited by 41
RetractedNanoformulations of doxorubicin: how far have we come and where do we go from here?
Borišev, I. Đ., Mrdjanović, J., Petrović, D., Seke, M., Jović, D., Čonić, B. S., Latinovic, N., & Djordjevic, A. N. (2018) · Nanotechnology · doi:10.1088/1361-6528/aac7dd · Cited by 38
“Furthermore, oral application of DOX encapsulated in poly (lactic-co-glycolic acid) nanoparticles to rats with breast cancer resulted in significant decrease in DOX-induced cardiotoxicity, as well as in greater antitumor efficacy in vivo, which authors attributed to combined effect of enhanced oral bioavailability and…”
BackgroundMartins, S. M., Wendling, T., Gonçalves, V. M. F., Sarmento, B. F. C. C., & Ferreira, D. (2011) · Journal of Chromatography B · doi:10.1016/j.jchromb.2011.11.023 · Cited by 36
Sheokand, S., Navik, U., & Bansal, A. K. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.12.006 · Cited by 36
He, M., Potuck, A., Kohn, J. C., Fung, K., Reinhart‐King, C. A., & Chu, C. (2015) · Biomacromolecules · doi:10.1021/acs.biomac.5b01449 · Cited by 34
Jain, A., Thanki, K., & Jain, S. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1214-1 · Cited by 31
“Tumor was induced by oral administration of 7, 12-dimethyl[α] benzanthracene (DMBA) solution (in soybean oil) to female SD rats (200–230 g) at the dose of 45 mg/kg at weekly interval for three consecutive weeks (4,40).”
MethodSelf-citationFunctionalized Mesoporous Silica as Doxorubicin Carriers and Cytotoxicity Boosters
Racleş, C., Zaltariov, M., Peptanariu, D., Vasiliu, T., & Cazacu, M. (2022) · Nanomaterials · doi:10.3390/nano12111823 · Cited by 30
Biodegradable Polymers for Potential Delivery Systems for Therapeutics
Pandey, S. K., Haldar, C., Patel, D. K., & Maiti, P. (2013) · Advances in polymer science · doi:10.1007/12_2012_198 · Cited by 31
Wang, J., Li, L., Du, Y., Sun, J., Han, X., Luo, C., Ai, X., Zhang, Q., Wang, Y., Fu, Q., et al. (2015) · Molecular Pharmaceutics · doi:10.1021/mp500833m · Cited by 29
Swarnakar, N. K., Thanki, K., & Jain, S. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400601g · Cited by 33
Self-citationPolymeric nanoparticles as a platform for permeability enhancement of class III drug amikacin
Fatima, S., Iqbal, Z., Panda, A. K., Samim, M., Talegaonkar, S., & Ahmad, F. J. (2018) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2018.05.028 · Cited by 28
Tariq, M., Alam, A., Singh, A. T., Panda, A. K., & Talegaonkar, S. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.01.054 · Cited by 27
“Similarly, better pharmacodynamic profile was reported for doxorubicin and paclitaxel by exploiting PLGA NPs (Bhardwaj et al., 2009; Jain et al., 2011a).”
BackgroundAdvances in oral delivery of anti-cancer prodrugs
Jain, A., & Jain, S. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1200554 · Cited by 27
“great challenge, owing to the atypical physicochemical properties of anticancer drugs [5,6], physiological/biological”
BackgroundSelf-citationNanotoxicology: Toxicity and Risk Assessment of Nanomaterials *Equal contribution
Saifi, M. A., Khurana, A., & Godugu, C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812792-6.00017-0 · Cited by 31
Self-citationSingh, R. P., Jain, S., & Ramarao, P. (2013) · Journal of Nanoparticle Research · doi:10.1007/s11051-013-1985-7 · Cited by 25
“They also show high oral absorption resulting in high bioavailability, higher therapeutic efficacy, reduced toxicity and tissue targeting (Jain et al. 2011a, b).”
BackgroundSelf-citationSwarnakar, N. K., Thanki, K., & Jain, S. (2013) · RSC Advances · doi:10.1039/c3ra41107a · Cited by 23
Self-citationGurushankar, K., Nazeer, S. S., Jayasree, R. S., & Krishnakumar, N. (2015) · Journal of Fluorescence · doi:10.1007/s10895-015-1575-4 · Cited by 23
Jäger, E., Humajová, J., Dölen, Y., Kučka, J., Jäger, A., Konefał, R., Pankrác, J., Pavlová, E., Heizer, T., Šefc, L., et al. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202100304 · Cited by 18
Ibrahim, M., Fathalla, Z. M. A., Fatease, A. M. A., Alamri, A. H., & Abdelkader, H. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2412823 · Cited by 21
“The increase in the permeation and cellular uptake of doxorubicin was found to reduce the tumor burden by 49.06% upon oral administration of doxorubicin loaded PLGA-NPs compared to an increase in the tumor burden by 158% in case of untreated group [114].”
InfluentialTariq, M., Alam, A., Singh, A. T., Panda, A. K., & Talegaonkar, S. (2016) · Drug Delivery · doi:10.3109/10717544.2015.1136713 · Cited by 16
“Email: stalegaonkar@gmail.com stalegaonkar@jamaiahamdard@ac.in. inhibition, and immune suppression which may lead to longterm medical complications (Jain et al., 2011a).”
BackgroundInfluentialŞengel-Türk, C. T., Gümüştaş, M., Uslu, B., & Özkan, S. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-52727-9.00010-8 · Cited by 18
Nanotechnology for oral delivery of anticancer drugs: an insight potential
Gupta, M., Sharma, V., & Chauhan, N. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-47720-8.00017-1 · Cited by 15
Sethi, S., Bhatia, S., Kamboj, S., & Rana, V. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120720 · Cited by 14
Polymeric Nanoparticles: In Vivo Toxicological Evaluation, Cardiotoxicity, and Hepatotoxicity
García, S. C., Guterres, S. S., Bubols, G., Bulcão, R., Charão, M. F., & Pohlmann, A. R. (2013) · Nanomedicine and nanotoxicology · doi:10.1007/978-1-4614-8993-1_14 · Cited by 13
Bolat, Z. B., Nezir, A. E., Devrim, B., Zemheri, E. I., Gülyüz, S., Özköse, U. U., Yılmaz, Ö., Bozkır, A., Telci, D., & Şahin, F. (2021) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2021.115671 · Cited by 13
Multifunctional Nanotherapeutics for Intracellular Trafficking of Doxorubicin Against Breast Cancer
Kurmi, B. D., Patel, P., Paliwal, R., Kumar, P., & Paliwal, S. R. (2023) · Nanomedicine · doi:10.2217/nnm-2023-0087 · Cited by 12
Ahmad, F. J., Fatima, S., Panda, A., Talegaonkar, S., & Iqbal, Z. (2019) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/jpbs.jpbs_60_18 · Cited by 12
“[26] Thus, for obtaining particles with low particle size, optimum homogenization time, probe sonication time, and drug/polymer ratio were identified in the three-dimensional (3D) surface diagrams [Figure 8]. by homogenization-induced net shear stress.”
InfluentialBofill-Bonet, C., Gil-Vives, M., Artigues, M., Hernández, M., Borrós, S., & Fornaguera, C. (2023) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2023.122986 · Cited by 12
Khan, A. M., Ahmad, F. J., Panda, A. K., & Talegaonkar, S. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.05.008 · Cited by 11
Andrade‐Gagnon, B., & Oh, J. K. (2024) · Polymer Chemistry · doi:10.1039/d4py00660g · Cited by 7
A poly- l -glutamic acid functionalized nanocomplex for improved oral drug absorption
Zhu, Q., Song, W., Xia, D., Fan, W., Yu, M., Guo, S., Zhu, C., & Gan, Y. (2015) · Journal of Materials Chemistry B · doi:10.1039/c5tb01425e · Cited by 7
Excipients used in oral nanocarrier-based formulations
Jog, R., & Burgess, D. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-51255-8.00010-0 · Cited by 8
Extending the Shelf Life of Doxorubicin Loaded PLGA Nanoparticles with Cryoprotectants
Koldankaya, T., & Mert, S. (2024) · ChemistrySelect · doi:10.1002/slct.202401759 · Cited by 3
The Pico- to Nanosecond Dynamics of Phospholipid Molecules
Busch, V. E. S. (2012) · iMPULSE (Heinz Maier-Leibnitz Zentrum) · Cited by 4
Ouyang, Y., Meng, F., Du, M., Ma, Q., Liu, H., Zhuang, Y., Pang, M., Cai, T., & Cai, Y. (2022) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902022e19245 · Cited by 2
Probiotic-derived microcarriers enhance the oral bioavailability of poorly absorbed anticancer drugs
Kim, H., Lee, S.-S., Kim, Y., Jang, K., Kim, S., Hwang, I., & Chung, D. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125799 · Cited by 2
Carbon Nanomaterials for Therapy, Diagnosis, and Biosensing
Mazzaglia, A., & Piperno, A. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-4512-7 · Cited by 2
Sethi, S., Bhatia, S., Kamboj, S., Singh, R. S., & Rana, V. (2021) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2022.2083153 · Cited by 1
“For the induction of disease, female SD rats of 45–50 days age were administered with 7,12-dimethylbenz[a]anthracene (DMBA) in sesame oil orally (45mg/kg) at a weekly interval for three consecutive weeks [25].”
MethodSelf-citationPeroral Polyester Drug Delivery Systems
Durán‐Lobato, M., Holgado, M. A., Álvarez‐Fuentes, J., Arias, J. L., Arévalo, M. F., & Martín‐Banderas, L. (2016) · Pan Stanford eBooks · doi:10.1201/b20045-10
Lectin-coated particulate delivery systems for oral administration
Reis, C. P., Ramalhete, N., & Fitas, M. (2016) · doi:10.4155/fseb2013.13.109
Meng, J., Jiang, X., Yuan, Y., Han, S., & Qian, F. (2025) · Advanced Therapeutics · doi:10.1002/adtp.202500085
Talele, K. R., & Bhattacharya, S. (2026) · Colloid & Polymer Science · doi:10.1007/s00396-026-05626-5
Metadata
- Authors
- Jain, A. K., Swarnakar, N. K., Das, M., Godugu, C., Singh, R. P., Rao, P. R., & Jain, S.
- Affiliations
- National Institute of Pharmaceutical Education and Research (IN)
- Corresponding author
- Jain, Sanyog
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2011-05-25
- Volume
- 8
- Issue
- 4
- Pages
- 1140-1151
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W2332972932
- Cited by
- 89
- References
- 52
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 4 · 2022: 7 · 2021: 5 · 2020: 2 · 2019: 3 · 2018: 12 · 2017: 5 · 2016: 7 · 2015: 10 · 2014: 4 · 2013: 15 · 2012: 7
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Pharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- doxorubicin, PLGA nanoparticles, oral drug delivery, breast cancer, cardiotoxicity, nanoparticle cytotoxicity, cellular uptake, freeze-drying, Caco-2 cells, tumor growth inhibition, antioxidant enzymes, cardiac histopathology
- MeSH terms
- Polylactic Acid-Polyglycolic Acid Copolymer, Animals, Antineoplastic Agents, Breast Neoplasms, Creatine Kinase, Doxorubicin, Female, Glutathione, Humans, L-Lactate Dehydrogenase, Malondialdehyde, Polyglycolic Acid, Superoxide Dismutase, Rats, Sprague-Dawley, Microscopy, Atomic Force, Caco-2 Cells, Lactic Acid, Cell Line, Tumor, Mice, Kaplan-Meier Estimate, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.